NCT05572281View on ClinicalTrials.gov

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Healthy
Interventions
DRUG

Tasimelteon Oral Capsule

No additional information

DRUG

Tasimelteon Oral Suspension

No additional information

Trial Locations (1)

65802

Vanda Investigational Site, Springfield

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY